Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology
Anurag Bhalla, Manali Mukherjee, Katherine Radford, Ishac Nazy, Melanie Kjarsgaard, Dawn M. E. Bowdish, Parameswaran Nair
Abstract
Dr Bhalla is supported by the Frederick E. Hargreave fellowship in Airway Diseases. Ms Radford, Ms Kjarsgaard, and Dr Nazy do not have any disclosures. Dr Mukherjee is supported by investigator award from Canadian Institutes of Health Research and Canadian Allergy, Asthma, and Immunology Foundation. She has received grants from Methapharm Specialty Pharmaceuticals and honorarium from AZ. Dr Bowdish is supported by a Canada Research Chair in Aging & Immunity. She has received honoraria from Pfizer, Astra Zeneca, and Abbvie. Dr Nair is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. He has received honoraria from AZ, Sanofi, Teva, Merck, Novartis, and Equillium, and his university has received research grants from AZ, Teva, Sanofi, Novartis, BI, and Methapharm.